Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score

Katja Gwin, Marguerite Pinto, Fattaneh A. Tavassoli

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Oncotype DX is a 21-gene assay that quantifies the recurrence risk in estrogen receptorg-positive breast cancer, which is expressed as the recurrence score (RS). Studies have shown that patients with a high-risk RS will most likely benefit from adjuvant chemotherapy, but there is no proven advantage for patients with a low-risk RS who still face an average recurrence risk of 7%. In this study, the relationship between the RS and the cell cycleg-related antigen Ki-67 was assessed in 32 breast carcinomas and evaluated for a potential association. Comparison of the RS with tumor type, grade, and the Ki-67 proliferation index (PI) revealed an overall concordance. However, some tumors with a low RS revealed a surprisingly high Ki-67 PI. These cases may correspond to the 7% of low-risk RS carcinomas that recur. Therefore, the authors propose a combined evaluation of the RS and Ki-67 PI to identify tumors with high recurrence potential from the low-risk and intermediate-risk RS groups.

Original languageEnglish (US)
Pages (from-to)303-310
Number of pages8
JournalInternational Journal of Surgical Pathology
Volume17
Issue number4
DOIs
StatePublished - Aug 2009

Fingerprint

Recurrence
Ki-67 Antigen
Breast Neoplasms
Neoplasms
Adjuvant Chemotherapy
Estrogens
Carcinoma
Genes

Keywords

  • Breast
  • Carcinoma
  • Ki-67
  • Molecular profiling
  • Oncotype DX
  • Prognosis
  • Recurrence score

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine
  • Surgery

Cite this

Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score. / Gwin, Katja; Pinto, Marguerite; Tavassoli, Fattaneh A.

In: International Journal of Surgical Pathology, Vol. 17, No. 4, 08.2009, p. 303-310.

Research output: Contribution to journalArticle

@article{2156f8d90f144f409834eb207f4156ba,
title = "Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score",
abstract = "Oncotype DX is a 21-gene assay that quantifies the recurrence risk in estrogen receptorg-positive breast cancer, which is expressed as the recurrence score (RS). Studies have shown that patients with a high-risk RS will most likely benefit from adjuvant chemotherapy, but there is no proven advantage for patients with a low-risk RS who still face an average recurrence risk of 7{\%}. In this study, the relationship between the RS and the cell cycleg-related antigen Ki-67 was assessed in 32 breast carcinomas and evaluated for a potential association. Comparison of the RS with tumor type, grade, and the Ki-67 proliferation index (PI) revealed an overall concordance. However, some tumors with a low RS revealed a surprisingly high Ki-67 PI. These cases may correspond to the 7{\%} of low-risk RS carcinomas that recur. Therefore, the authors propose a combined evaluation of the RS and Ki-67 PI to identify tumors with high recurrence potential from the low-risk and intermediate-risk RS groups.",
keywords = "Breast, Carcinoma, Ki-67, Molecular profiling, Oncotype DX, Prognosis, Recurrence score",
author = "Katja Gwin and Marguerite Pinto and Tavassoli, {Fattaneh A.}",
year = "2009",
month = "8",
doi = "10.1177/1066896909340274",
language = "English (US)",
volume = "17",
pages = "303--310",
journal = "International Journal of Surgical Pathology",
issn = "1066-8969",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score

AU - Gwin, Katja

AU - Pinto, Marguerite

AU - Tavassoli, Fattaneh A.

PY - 2009/8

Y1 - 2009/8

N2 - Oncotype DX is a 21-gene assay that quantifies the recurrence risk in estrogen receptorg-positive breast cancer, which is expressed as the recurrence score (RS). Studies have shown that patients with a high-risk RS will most likely benefit from adjuvant chemotherapy, but there is no proven advantage for patients with a low-risk RS who still face an average recurrence risk of 7%. In this study, the relationship between the RS and the cell cycleg-related antigen Ki-67 was assessed in 32 breast carcinomas and evaluated for a potential association. Comparison of the RS with tumor type, grade, and the Ki-67 proliferation index (PI) revealed an overall concordance. However, some tumors with a low RS revealed a surprisingly high Ki-67 PI. These cases may correspond to the 7% of low-risk RS carcinomas that recur. Therefore, the authors propose a combined evaluation of the RS and Ki-67 PI to identify tumors with high recurrence potential from the low-risk and intermediate-risk RS groups.

AB - Oncotype DX is a 21-gene assay that quantifies the recurrence risk in estrogen receptorg-positive breast cancer, which is expressed as the recurrence score (RS). Studies have shown that patients with a high-risk RS will most likely benefit from adjuvant chemotherapy, but there is no proven advantage for patients with a low-risk RS who still face an average recurrence risk of 7%. In this study, the relationship between the RS and the cell cycleg-related antigen Ki-67 was assessed in 32 breast carcinomas and evaluated for a potential association. Comparison of the RS with tumor type, grade, and the Ki-67 proliferation index (PI) revealed an overall concordance. However, some tumors with a low RS revealed a surprisingly high Ki-67 PI. These cases may correspond to the 7% of low-risk RS carcinomas that recur. Therefore, the authors propose a combined evaluation of the RS and Ki-67 PI to identify tumors with high recurrence potential from the low-risk and intermediate-risk RS groups.

KW - Breast

KW - Carcinoma

KW - Ki-67

KW - Molecular profiling

KW - Oncotype DX

KW - Prognosis

KW - Recurrence score

UR - http://www.scopus.com/inward/record.url?scp=68349160478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68349160478&partnerID=8YFLogxK

U2 - 10.1177/1066896909340274

DO - 10.1177/1066896909340274

M3 - Article

C2 - 19578051

AN - SCOPUS:68349160478

VL - 17

SP - 303

EP - 310

JO - International Journal of Surgical Pathology

JF - International Journal of Surgical Pathology

SN - 1066-8969

IS - 4

ER -